HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Hims & Hers Health (NYSE ... including Eli Lilly’s highly sought-after Zepbound. However, if you seek upside with less volatility than a single stock, consider the High-Quality portfolio ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV commercials in the first quarter compared to the same period a year ago. | ...

Trial data data showed Lilly's experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer ...

Companies like Hims & Hers and WeightWatchers have been ... approved, and studied Zepbound for patients who are being asked to pay out-of-pocket," he added. Jonsson also told Reuters that more ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... with shares of Hims & Hers Health, a company offering compounded versions of GLP-1 treatments ...